Screener
Rapport Therapeutics, Inc. RAPP Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -40%-10.5pp | -28.3%— | -28.2%— | -23.4%— | -29.4%— | |
| Return on invested capital | -52.1%-6.7pp | -38.2%— | -36.1%— | -39.5%— | -45.3%— | |
| Liquidity | ||||||
| Current ratio | 15.7×-7.0× | 27.1×-3.9× | 26.2×-9.2× | 36.4×-9.5× | 22.7×-19.3× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $8.91+19.8% | $9.98+23.2% | $12.45-15.5% | $13.49+45.5% | $7.43-76.5% | |
| Valuation | ||||||
| Market capitalization | $2.22B+317% | $1.5B+309% | $1.45B+123% | $1.37B+82.8% | $451.84M-46.9% | |
| Price / book | 5.3×+3.2× | 3.2×+1.9× | 3×+0.9× | 2.7×+0.4× | 1.7×-0.8× |
FAQ
- Where do Rapport Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Rapport Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
